Elevated thymidine kinase 1 in serum following neoadjuvant chemotherapy predicts poor outcome for patients with locally advanced breast cancer

Experimental and Therapeutic Medicine

Volumn 3, Issue 2, 2012, Pages 331-335

  Huang, Zhi Heng ^a,b   Tian, Xing Song ^a   Li, Rong ^b   Wang, Xian Ming ^b   Wen, Wen ^c   Guan, Hong ^c   Yang, Ya Jie ^c  

^a SHANDONG UNIVERSITY   (China)

^b SHENZHEN UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SHENZHEN UNIVERSITY   (China)

Author keywords

Locally advanced breast cancer; Neoadjuvant chemotherapy; Thymidine kinase 1

Indexed keywords

THYMIDINE KINASE 1;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; EXPERIMENTAL DESIGN; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LOCALLY ADVANCED BREAST CANCER; PATIENT COMPLIANCE;

EID: 84855372667     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.395     Document Type: Article

References (33)

1. Hortobagyi GN: Comptehensive management of locally advanced breast cancer. Cancer 66: 1387-1391, 1990.
2. Hortobagyi GN, Ames FC, Buzdar AU, et al: Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62: 2507-2516, 1988.
3. Fisher B, Gunduz N and Saffer EA: Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 43: 1488-1492, 1983.
4. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685, 1998.
5. Goble S and Bear HD: Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions. Surg Clin North Am 83: 943-971, 2003.
6. Chang JC, Wooten EC, Tsimelzon A, et al: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362: 362-369, 2003.
7. Scholl SM, Pierga JY, Assselain B, et al: Breast tumor response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 31A: 1969-1975, 1995.
8. Semiglazov VF, Topuzov EE, Bavli JL, et al: Primary chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIIb-IIIa breast cancer. Ann Ocol 5: 591-595, 1994.
9. Makris A, Powles TJ, Dowsett M, et al: Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 3: 593-600, 1997.
10. Mauriac L, MacGrogan G, Avril A, et al: Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institute Bergonie Bordeaux Groupe Sein. Ann Oncol 10: 47-52, 1999.
11. van der Hage JA, van der Velde CJ, Julien JP, et al: Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19: 4224-4237, 2000.
12. Hu CM and Chang ZF: Mitotic control of dTTP pool: a necessary or coincidence? J Biomed Sci 14: 491-497, 2007.
13. Al-Madhoun AS, Tjarks W and Eriksson S: The role of thymidine kinase in the activation of pyrimidine nucleoside analogues. Mini Rev Med Chem 4: 341-350, 2004.
14. Wu C, Yang R, Zhou J, et al: Production and characterization of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1. J Immunol Methods 277: 157-169, 2003.
15. Gowda A and Byrd JC: Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia. Curr Opin Hematol 13: 266-272, 2006.
16. Madewell BR: Serum thymidine kinase activity: an alternative to histologic markers of cellular proliferation in canine lymphoma. J Vet Intern Med 18: 595-596, 2004.
17. Di RF, Giustolisi R, Lerner S, et al: Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. Ann Oncol 12: 621-625, 2001.
18. Schwartz MK: Enzymes as prognostic markers and therapeutic indicators in patients with cancer. Clin Chim Acta 206: 77-82, 1992.
19. O'Neill KL, Zhang F, Li H, et al: Thymidine kinase1 - a prognostic and diagnostic indicator in ALL and AML patients. Leukemia 21: 560-563, 2007.
20. Zhang J, Jia Q, Zou S, et al: Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncol Rep 15: 455-461, 2006.
21. Fujiwaki R, Hata K, Moriyama M, et al: Clinical value of thymidine kinase in patients with cervical carcinoma. Oncology. 61: 47-54, 2001.
22. Tiezzi D, Andrate J, Ribeiro-Silva A, et al: HER-2, p53, p21 and hormonal receptor protein expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer 7: 36, 2007.
23. Singletary S, McNeese M, Hortobagyi G, et al: Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer 69: 2849-2852, 1992.
24. Alassas M, Chu Q, Burton G, et al: Neoadjuvant chemotherapy in stage III breast cancer. Am Surgeon 71: 487-492, 2005.
25. Isaccs C, Stearns V and Hayes DF: New prognostic factors for breast cancer recurrence. Semin Oncol 28: 53-67, 2001.
26. Gianni L, Zambetti M, Clark K, et al: Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23: 7265-7277, 2005.
27. Hess K, Anderson K, Symmans W, et al: Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin and cyclophosphamide in breast cancer. J Clin Oncol 24: 4236-4244, 2006.
28. Sorlie T, Perou C, Fan C, et al: Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther 5: 2914-2918, 2006.
29. Piega J, Reis-Filho J, Cleator S, et al: Micro-array-based comparative genomic hybridization of breast cancer patients receiving neoadjuvant chemotherapy. Br J Cancer 96: 341-351, 2007.
30. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004.
31. Palangie T, Mosseri V, Mihura J, et al: Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer 30A: 921-927, 1994.
32. Honkoop A, van Diest P, de Jong J, et al: Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 77: 621-626, 1998.
33. Holm N, Byrnes K, Li B, et al: Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence. J Surg Res 141: 53-59, 2007.